Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
  • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/20—Spiro-condensed ring systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/10—Spiro-condensed systems

Definitions

• Vasopressin is a 9 amino acid peptide mainly produced by the paraventricular nucleus of the hypothalamus. Three vasopressin receptors, all belonging to the class I G-protein coupled receptors, are known.
• the V1a receptor is expressed in the brain, liver, vascular smooth muscle, lung, uterus and testis, the V1b or V3 receptor is expressed in the brain and pituitary gland, the V2 receptor is expressed in the kidney where it regulates water excretion and mediates the antidiuretic effects of vasopressin.
• vasopressin acts as a neurohormone and stimulates vasoconstriction, glycogenolysis and antidiuresis.
• vasopressin acts as a neuromodulator and is elevated in the amygdala during stress (Ebner, K., C. T. Wotjak, et al. (2002). “Forced swimming triggers vasopressin release within the amygdala to modulate stress-coping strategies in rats.” Eur J Neurosci 15(2): 384-8).
• the V1a receptor is extensively expressed in the brain and particularly in limbic areas like the amygdala, lateral septum and hippocampus which are playing an important role in the regulation of anxiety.
• V1a knock-out mouse show a reduction in anxious behavior in the plus-maze, open field and light-dark box (Bielsky, I. F., S. B. Hu, et al. (2003). “Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice.” Neuropsychopharmacology ).
• the downregulation of the V1a receptor using antisense oligonucleotide injection in the septum also causes a reduction in anxious behavior (Landgraf, R., R. Gerstberger, et al. (1995). “V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats.” Regul Pept 59(2): 229-39).
• the V1a receptor is also mediating the cardiovascular effects of vasopressin in the brain by centrally regulating blood pressure and heart rate in the solitary tract nucleus (Michelini, L. C. and M. Morris (1999). “Endogenous vasopressin modulates the cardiovascular responses to exercise.” Ann N Y Acad Sci 897: 198-211). In the periphery it induces the contraction of vascular smooth muscles and chronic inhibition of the V1a receptor improves hemodynamic parameters in myocardial infarcted rats (Van Kerckhoven, R., I. Lankhuizen, et al. (2002). “Chronic vasopressin V(1A) but not V(2) receptor antagonism prevents heart failure in chronically infarcted rats.” Eur J Pharmacol 449(1-2): 135-41).
• the present invention provides novel spiro-piperidine derivatives as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.
• R 5 and R 5 ′ are each independently hydrogen or methyl;
• R 6 is hydrogen or C 1-6 -alkyl;
• R 7 , R 7 ′, R 8 , R 8 ′ and R 9 are each independently selected from
• R 7 and R 8 , R 7 ′ and R 8 ′, R 8 and R 9 , or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
• the compounds of formula (I) can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the text or in the examples, or by methods known in the art.
• the compounds of formula (I) possess pharmaceutical activity, in particular they are modulators of V1a receptor activity. More particular, the compounds are antagonists of the V1a receptor. Such antagonists are useful as therapeutics in the conditions of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.
• the preferred indications with regard to the present invention are the treatment of anxiety and depressive disorders.
• alkyl refers to a branched or straight-chain monovalent saturated hydrocarbon radical.
• C 1-6 -alkyl denotes a saturated straight- or branched-chain hydrocarbon group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, the isomeric pentyls and the like.
• a preferred sub-group of C 1-6 -alkyl is C 1-4 -alkyl, i.e. with 1-4 carbon atoms.
• alkylene refers to a linear or branched saturated divalent hydrocarbon radical.
• C 1-6 -alkylene means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g. methylene, ethylene, 2,2-dimethylethylene, n-propylene, 2-methylpropylene, and the like.
• alkoxy and C 1-6 -alkoxy refers to the group R′—O—, wherein R′ is alkyl or C 1-6 -alkyl as defined above.
• alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy and the like.
• a preferred sub-group of C 1-6 -alkoxy, and still more preferred alkoxy groups are methoxy and/or ethoxy.
• thioalkyl and “C 1-6 -thioalkyl” refers to the group R′—S—, wherein R′ is alkyl or C 1-6 -alkyl as defined above.
• C 1-6 -hydroxyalkyl or “C 1-6 -alkyl substituted by OH” denotes a C 1-6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a hydroxyl group.
• C 1-6 -cyanoalkyl or “C 1-6 -alkyl substituted by CN” denotes a C 1-6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a CN group.
• halo or “halogen” refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I) with fluorine, chlorine and bromine being preferred.
• halo-C 1-6 -alkyl is synonymous with “C 1-6 -haloalkyl” or “C 1-6 -alkyl substituted by halo” and means a C 1-6 -alkyl group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
• halo-C 1-6 -alkyl examples include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
• preferred halo-C 1-6 -alkyl groups are difluoro- or trifluoro-methyl or -ethyl.
• halo-C 1-6 -alkoxy is synonymous with “C 1-6 -haloalkoxy” or “C 1-6 -alkoxy substituted by halo” and means a C 1-6 -alkoxy group as defined above wherein at least one of the hydrogen atoms of the alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro.
• halogenated alkoxy groups are difluoro- or trifluoro-methoxy or -ethoxy.
• C 2-12 -alkenyl denotes a straight-chain or branched hydrocarbon residue of 2 to 12 carbon atoms comprising at least one double bond.
• a preferred sub-group of C 2-12 -alkenyl is C 2-6 -alkyenyl.
• Examples of the preferred alkenyl groups are ethenyl, propen-1-yl, propen-2-yl (allyl), buten-1-yl, buten-2-yl, buten-3-yl, penten-1-yl, penten-2-yl, penten-3-yl, penten-4-yl, hexen-1-yl, hexen-2-yl, hexen-3-yl, hexen-4-yl and hexen-5-yl, as well as those specifically illustrated by the examples herein below.
• substituents preferably means one, two or three optional substituents per ring.
• “Pharmaceutically acceptable,” such as pharmaceutically acceptable carrier, excipient, etc., means pharmacologically acceptable and substantially non-toxic to the subject to which the particular compound is administered.
• pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
• “Therapeutically effective amount” means an amount that is effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.
• bound together to form a ring with the phenyl moiety means that the residues of the phenyl ring, which are located in ortho-position to each other, may form an anellated ring to the phenyl moiety.
• the invention further comprises individual optical isomers of the compounds herein as well as racemic and non-racemic mixtures thereof.
• R 5 and R 5 ′ are each independently hydrogen or methyl;
• R 6 is hydrogen or C 1-6 -alkyl;
• R 7 , R 7 ′, R 8 , R 8 ′, and R 9 are each independently selected from
• R 7 and R 8 , R 7 ′ and R 8 ′, R 8 and R 9 , or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
• R 1 , R 2 , R 3 and R 4 are each independently hydrogen, halo, C 1-6 -alkyl or C 1-6 -alkoxy, optionally substituted by OH.
• R 1 is hydrogen or halo, preferably hydrogen or fluoro.
• R 2 is hydrogen, halo or C 1-6 -alkoxy; preferably hydrogen, fluoro, bromo or methoxy.
• R 3 is hydrogen, halo, or C 1-6 -alkoxy, optionally substituted by OH; preferably hydrogen, chloro, bromo, methoxy or —O(CH 2 ) 2 OH.
• R 4 is hydrogen or C 1-6 -alkyl; preferably hydrogen or methyl.
• all R 1 to R 4 are hydrogen.
• one residue of R 1 to R 4 is halo and the others are hydrogen.
• one residue of R 1 to R 4 is C 1-6 -alkyl, preferably methyl, and the others are hydrogen.
• one residue of R 1 to R 4 is C 1-6 -alkoxy, optionally substituted by OH, preferably methoxy or —O(CH 2 ) 2 OH, and the others are hydrogen.
• R 5 and R 5 ′ are both hydrogen, in other embodiments of the invention, R 5 and R 5 ′ are both methyl, in other embodiments of the invention, R 5 is hydrogen and R 5 ′ is methyl.
• R 5 is hydrogen, R 5 ′ is methyl, X is O and Y is C ⁇ O.
• R 6 is hydrogen or C 1-6 -alkyl, preferably hydrogen.
• both R 7 and R 7 ′ are hydrogen.
• one of R 7 and R 7 ′ is hydrogen and the other is halo, halo-C 1-6 -alkyl, C 1-6 -alkyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, nitro, or cyano.
• R 7 and R 7 ′ are each independently hydrogen or halo.
• one of R 7 and R 7 ′ is hydrogen and the other is halo, preferably chloro.
• each of R 8 and R 8 ′ are independently hydrogen, halo, halo-C 1-6 -alkyl, C 1-6 -alkyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, nitro, or cyano.
• R 8 and R 8 ′ are each independently hydrogen, halo, or C 1-6 -alkoxy, preferably hydrogen, chloro, ethoxy or methoxy.
• R 7 and R 8 or R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety, wherein
• R 7 and R 8 are bound together to form a ring with the phenyl moiety as described above, and
• R 9 , R 8 ′ and R 7 ′ are hydrogen
• R 9 and R 7 ′ are hydrogen, and R 8 ′ is halo, preferably chloro, or
• R 9 and R 7 ′ are hydrogen, and R 8 ′ is C 1-6 -alkoxy, preferably ethoxy or methoxy.
• R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety as described above, and
• R 9 , R 8 and R 7 are hydrogen
• R 9 and R 7 are hydrogen, and R 8 is halo, preferably chloro, or
• R 9 and R 7 are hydrogen, and R 8 is C 1-6 -alkoxy, preferably ethoxy or methoxy.
• R 7 and R 8 are halo, preferably chloro, and R 9 , R 7 ′ and R 8 ′ are hydrogen.
• R 9 is hydrogen, halo, halo-C 1-6 -alkyl, C 1-6 -alkyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, nitro, or cyano.
• R 9 is hydrogen, halo, or C 1-6 -alkyl, preferably hydrogen, chloro or tert-butyl.
• R 8 and R 9 or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
• R 8 and R 9 are bound together to form a ring with the phenyl moiety as described above, and R 7 , R 8 ′ and R 7 ′ are hydrogen.
• R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety as described above, and R 7 , R 8 and R 7 ′ are hydrogen.
• R 8 and R 9 are halo, preferably chloro, and R 7 , R 7 ′ and R 8 ′ are hydrogen.
• R 8 ′ and R 9 are halo, preferably chloro, and R 7 , R 7 ′ and R 8 ′′ are hydrogen.
• R 9 is C 1-6 -alkyl or halo, preferably tert-butyl or chloro, and R 7 , R 7 ′, R 8 , and R 8 ′ are hydrogen.
• Preferred compounds of the invention are those of formula (I) wherein
• R 8 and R 9 are halo, or wherein R 8 and R 9 are bound together to form a ring with the phenyl moiety, wherein
• Preferred compounds of the invention are those of formula (I) wherein
• R 8 ′ and R 9 are halo, or wherein R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
• R 7 , R 7 ′, R 8 , R 8 ′ and R 9 are not simultaneously hydrogen.
• a certain embodiment of the invention relates to a compound of formula (I)
• R 5 and R 5 ′ are each independently hydrogen or methyl;
• R 6 is hydrogen or C 1-6 -alkyl;
• R 7 and R 7 ′ are each independently selected from
• R 8 and R 8 ′ are each independently selected from
• R 7 and R 8 or R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety, wherein
• R 8 and R 9 or R 8 ′ and R 9 are bound together to form a ring with the phenyl moiety, wherein
• a certain embodiment of the invention relates to compounds of formula (I)
• R 5 and R 5 ′ are each independently hydrogen or methyl;
• R 6 is hydrogen or C 1-6 -alkyl;
• R 7 and R 7 ′ are each independently hydrogen or halo;
• R 8 and R 8 ′ are each independently hydrogen, halo, or C 1-6 -alkoxy;
• R 7 and R 8 or R 7 ′ and R 8 ′ are bound together to form a ring with the phenyl moiety, wherein
• the invention provides compounds of formula I wherein
• the invention provides compounds of formula I wherein
• the invention provides compounds of formula I wherein
• An embodiment of the invention relates to compounds of formula (I-a)
• R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
• An embodiment of the invention relates to compounds of formula (I-b)
• R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
• An embodiment of the invention relates to compounds of formula (I-c)
• R 1 to R 9 are as defined in any combination as described above.
• An embodiment of the invention relates to compounds of formula (I-d)
• R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
• An embodiment of the invention relates to compounds of formula (I-e)
• R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
• An embodiment of the invention relates to compounds of formula (I-f)
• R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
• An embodiment of the invention relates to compounds of formula (I-g)
• R 1 to R 5 ′ and R 7 to R 9 are as defined in any combination as described above.
• An embodiment of the invention relates to compounds of formula (I-h)
• R 1 to R 9 are as defined in any combination as described above.
• Any compound of formula (I-a) to (I-h) may be combined with any residue or combination of residues R 1 to R 9 as defined above.
• Preferred compounds are those of formula (I-a) to (I-f).
• Preferred compounds of the invention are those of the examples. More preferred are the following compounds:
• the invention also encompasses methods for the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders which comprises administering an effective amount of a compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h).
• the invention also encompasses a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) or (I-h) and a pharmaceutically acceptable carrier.
• the pharmaceutical composition may further comprise at least one pharmaceutically acceptable excipient.
• the compound of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
• the compound of the invention can be manufactured according to a process comprising reacting a compound of formula (II):
• the compounds of the present invention exhibit V1a activity, which may be detected as described below:
• the human V1a receptor was cloned by RT-PCR from total human liver RNA.
• the coding sequence was subcloned in an expression vector after sequencing to confirm the identity of the amplified sequence.
• Cell membranes were prepared from HEK293 cells transiently transfected with the expression vector and grown in 20 liter fermenters with the following protocol.
• the pellet was resuspended in 12.5 ml Lysis buffer+12.5 ml Sucrose 20% and homogenized using a Polytron for 1-2 min.
• the protein concentration was determined by the Bradford method, and aliquots were stored at ⁇ 80° C. until use.
• 60 mg Yttrium silicate SPA beads (Amersham) were mixed with an aliquot of membrane in binding buffer (50 mM Tris, 120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM MgCl2) for 15 minutes with mixing.
• the present invention also provides pharmaceutical compositions containing compounds of the invention, such as compounds of formula (I), and (Ia) to (If), or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
• Such pharmaceutical compositions can be in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions.
• the pharmaceutical compositions also can be in the form of suppositories or injectable solutions.
• compositions of the invention in addition to one or more compounds of the invention, contain a pharmaceutically acceptable carrier.
• suitable pharmaceutically acceptable carriers include pharmaceutically inert, inorganic or organic carriers.
• Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatine capsules.
• Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
• Suitable excipients for the manufacture of solutions and syrups are e.g. water, polyols, saccharose, invert sugar, glucose etc.
• Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
• Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
• compositions can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
• a daily dosage of about 10 to 1000 mg per person of a compound of general formula (I) should be appropriate, although the above upper limit can also be exceeded when necessary.
• the active substance, lactose and corn starch can be firstly mixed in a mixer and then in a comminuting machine.
• the mixture the can be returned to the mixer, the talc can be added thereto and mixed thoroughly.
• the mixture can be filled by machine into hard gelatine capsules.
• the suppository mass can be melted in a glass or steel vessel, mixed thoroughly and cooled to 45° C.
• the finely powdered active substance can be added thereto and stirred until it has dispersed completely.
• the mixture the can be poured into suppository moulds of suitable size, left to cool; the suppositories then can be removed from the moulds and packed individually in wax paper or metal foil.
• reaction mixture was added to a mixture of water (500 ml) and ether (300 mL).
• ether 300 mL
• the aqueous layer was extracted with ether (5 ⁇ 150 mL) and acidified with concentrated HCl (to pH 2-3) and extracted with ether (2 ⁇ 150 ml).
• the acidic solution was boiled for 1 h and then cooled to 0-5° C. and made alkaline (to pH 9-10) with aqueous NaOH.
• the cold solution was rapidly extracted with chloroform (5 ⁇ 300 mL).
• the combined chloroform extracts were washed with water (150 ml), dried over sodium sulfate and evaporated under reduced pressure.
• the residue was purified was purified by silica gel (100-200) column chromatography eluting with methanol in dichloromethane (0.5% to 2.5%) to afford 1 (4.2 g, 20%).
• the basic (aqueous) layer was extracted with ether (5 ⁇ 100 ml) and the aqueous layer was acidified with concentrated hydrochloric acid (pH 2-3) and extracted with ether.
• the aqueous solution was boiled for 1 h and was then cooled to 0-5° C. and made alkaline (pH 9-10) with cold aqueous sodium hydroxide.
• the cold solution was rapidly extracted with chloroform (5 ⁇ 200 ml).
• the combined chloroform extracts were washed with water, dried, concentrated to give light yellow solid which was purified over neutral alumina eluting with a gradient of 30-50% ethyl acetate-hexane to obtain 1.75 g (15%) of 9 as white solid.
• N-cyano lactone 5 (1.23 g, 5 mmol) was heated with ethylene glycol (5 ml) and sodium hydroxide (0.82 g, 20.5 mmol) for 15-20 min at 130° C. Most of the ethylene glycol was removed by distillation under high vacuum. The residual reaction mixture was diluted with water and extracted repeatedly with chloroform. The combined organics was dried and concentrated to give a semi solid material which was purified over Al2O3 column upon elution with 5-7% MeOH/CH 2 Cl 2 containing NH3 (aqueous) to yield 789 mg (60%) of CRI 1072 as pale yellow solid.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Neurology (AREA)
• Reproductive Health (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Pregnancy & Childbirth (AREA)
• Urology & Nephrology (AREA)
• Gynecology & Obstetrics (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Endocrinology (AREA)
• Gastroenterology & Hepatology (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Other In-Based Heterocyclic Compounds (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=39209551

Family Applications (3)

Family Applications Before (1)

Family Applications After (1)

Country Status (16)

Cited By (1)

Families Citing this family (6)

Citations (14)

Family Cites Families (35)

• 2007
  • 2007-12-13 US US11/955,452 patent/US8084609B2/en not_active Expired - Fee Related
  • 2007-12-13 EP EP12157626A patent/EP2535329A3/en not_active Withdrawn
  • 2007-12-13 US US11/955,460 patent/US20080153862A1/en not_active Abandoned
  • 2007-12-13 CN CNA2007800467360A patent/CN101563324A/zh active Pending
  • 2007-12-13 EP EP07857526A patent/EP2097376A2/en not_active Withdrawn
  • 2007-12-13 AU AU2007338115A patent/AU2007338115A1/en not_active Abandoned
  • 2007-12-13 US US11/955,466 patent/US20080153863A1/en not_active Abandoned
  • 2007-12-13 WO PCT/EP2007/063879 patent/WO2008077810A2/en active Application Filing
  • 2007-12-13 MX MX2009006454A patent/MX2009006454A/es not_active Application Discontinuation
  • 2007-12-13 JP JP2009542006A patent/JP2010513384A/ja active Pending
  • 2007-12-13 KR KR1020097012736A patent/KR20090082502A/ko active IP Right Grant
  • 2007-12-13 BR BRPI0721138-4A patent/BRPI0721138A2/pt not_active IP Right Cessation
  • 2007-12-13 RU RU2009123133/04A patent/RU2009123133A/ru not_active Application Discontinuation
  • 2007-12-13 CA CA002673307A patent/CA2673307A1/en not_active Abandoned
  • 2007-12-14 PE PE2007001809A patent/PE20081833A1/es not_active Application Discontinuation
  • 2007-12-19 TW TW096148806A patent/TW200833697A/zh unknown
  • 2007-12-20 CL CL200703720A patent/CL2007003720A1/es unknown
  • 2007-12-20 AR ARP070105764A patent/AR064481A1/es not_active Application Discontinuation
• 2009
  • 2009-06-03 NO NO20092149A patent/NO20092149L/no not_active Application Discontinuation

Patent Citations (15)

Also Published As

Similar Documents

Legal Events